Evidence map›Paper›PMID 34711015›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2021

CXCL1, CXCL10 and CXCL12 Chemokines are Variously Expressed in Acute Myeloid Leukemia Patients Prior and Post Bone Marrow Transplantation.

Bahar Yazdani, Gholamhossein Hassanshahi, Zahra Mousavi, Zahra Ahmadi, Hussein Khorramdelazad, Alireza Moradabadi, Mohamadreza Shafiepoor, Abbas Fatehi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Bahar YazdaniDepartment of Hematology and Blood Banking, Kerman University of Medical Sciences, Kerman, Iran.
Gholamhossein HassanshahiMolecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Zahra MousaviDepartment of Hematology and Medical Laboratory Sciences, Iranshahr University of Medical Sciences, Iranshahr, Iran.
Zahra AhmadiPistachio safety Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Hussein KhorramdelazadMolecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.ORCID 0000-0002-0653-2724
Alireza MoradabadiDepartment of Laboratory Sciences, Khomein University of Medical Sciences, Khomein, Iran.
Mohamadreza ShafiepoorDepartment of Internal Medicine, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Abbas FatehiDepartment of Pediatrics, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Rafsanjan University of Medical Sciences · IRImam Khomeini Hospital · IRIranshahr University · IRKerman University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe chemokine-receptor axes play parts in development of leukemia, CXCL1, CXCL10 and CXCL12 are involved in immune responses. Thus, we have examined the serum levels of these chemokines in parallel with their related cognate receptors (CXCR1, CXCR3 and CXCR4) in AML (acute myeloid leukemia) patients prior and post BMT (bone marrow transplantation) therapy. MAIN

methodsClinical specimens were collected from 46 AML patients (23 M1 and 23 M3 subtypes) before/after BMT. CXCL1, CXCL10 and CXCL12 concentrations were determined by ELISA. The mRNA levels of the related receptors were detected by QRT_PCR. Data were analyzed by T-test, χ2 and ANOVA statistical methods in SPSS software version 18. A difference was regarded significant if P value < 0.05. KEY

findingsOur results indicated that the elevated levels of CXCL12 in AML patients were remained unchanged after transplantation.  The CXCL10 concentration was decreased in patients. All studied chemokines were elevated in BMT patients with history of 9 times PLT transfusion. In patients who received BMT from siblings CXCL1 and CXCL10 have been elevated, whereby they were compared to patients who received BMT from parents while CXCL12 sustained unchanged in groups. Serum measures of CXCL1 and CXCL10 were induced in acute and chronic GVHD patients in compare to these without GVHD. SIGNIFICANCE: According to the results, it can be concluded that these chemokines play fundamental parts in pathogenesis of both AML and BMT. It is worthy to note that chemokines could be used as diagnostic markers alongside with possible promising therapeutic targets.

Indexed as

Bone Marrow TransplantationAdolescentAdultBiomarkers, TumorChemokine CXCL1Chemokine CXCL10Chemokine CXCL12ChildChild, PreschoolFemaleGraft vs Host DiseaseHumansLeukemia, Myeloid, AcuteMalePostoperative CarePreoperative CareBiomarkers, TumorChemokine CXCL1Chemokine CXCL10Chemokine CXCL12CXCL10 protein, humanCXCL12 protein, humanCXCL1 protein, humanCXCR3 protein, humanCXCR4 protein, humanReceptors, CXCR3Receptors, CXCR4Receptors, Interleukin-8AAMLBMTCXC chemokineCXC chemokine receptorLeukemia

Identifiers

PMID34711015
PMCPMC8858235
OpenAlexW3210136209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.